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Abstract
Physical activity is associated with disease prevention and overall wellbeing. Additionally there has been evidence that
physical activity level is a result of genetic influence. However, there has not been a reliable method to silence candidate
genes in vivo to determine causal mechanisms of physical activity regulation. Vivo-morpholinos are a potential method to
transiently silence specific genes. Thus, the aim of this study was to validate the use of Vivo-morpholinos in a mouse model
for voluntary physical activity with several sub-objectives. We observed that Vivo-morpholinos achieved between 60–97%
knockdown of Drd1-, Vmat2-, and Glut4-protein in skeletal muscle, the delivery moiety of Vivo-morpholinos (scramble) did
not influence physical activity and that a cocktail of multiple Vivo-morpholinos can be given in a single treatment to achieve
protein knockdown of two different targeted proteins in skeletal muscle simultaneously. Knocking down Drd1, Vmat2, or
Glut4 protein in skeletal muscle did not affect physical activity. Vivo-morpholinos injected intravenously alone did not
significantly knockdown Vmat2-protein expression in the brain (p = 0.28). However, the use of a bradykinin analog to
increase blood-brain-barrier permeability in conjunction with the Vivo-morpholinos significantly (p = 0.0001) decreased
Vmat2-protein in the brain with a corresponding later over-expression of Vmat2 coincident with a significant (p = 0.0016)
increase in physical activity. We conclude that Vivo-morpholinos can be a valuable tool in determining causal gene-
phenotype relationships in whole animal models.
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Introduction
Physical inactivity has been correlated with cardiovascular
disease, obesity, type II diabetes and some types of cancers [1].
With only 3.5% of adults meeting the recommended physical
activity guidelines [2], physical inactivity is the second leading
actual cause of death (,250,000 cases/year) in the United States
[3] with an estimated $507 billion a year in health care costs [1].
Several potential candidate genes associated with the genetic
influence on voluntary physical activity have been identified
[1,4,5,6,7,8,9,10,11] with potential regulatory effects both in the
brain and skeletal muscle.
Of the candidate genes identified, Dopamine Receptor 1 (Drd1;
[1,6,7,8,9]), Glucose Transporter 4 [Glut4, aka: Slc2a4; 11], and
Vesicular Monoamine Transporter 2 (Vmat2; [4,10,12,13]), have
been the most widely studied in association with voluntary physical
activity. Vmat2 is expressed in the brain and skeletal muscle.
Studies examining the nucleus accumbens of the brain have shown
that Vmat2 stores dopamine in synaptic vesicles [4,10,12,13]. A loss
of Vmat2 has been associated with a decrease in physical activity
and development of Parkinson’s disease [10,13]. Another central
factor contributing the regulation of physical activity is Drd1; high
active mice have an under expression of Drd1 which results in a
decrease in dopamine turnover in the nucleus accumbens [6] and
a suggested increase in reward driven behavior and voluntary
physical activity [6,7]. It has recently been proposed that Drd1
expression in skeletal muscle could have similar effects on physical
activity with an increase in D1 receptors (Drd1 and Drd5) in skeletal
muscle being associated with an increase in muscle force
production and prevention of atrophy [8]. An additional
mechanism by which peripheral factors could regulate physical
activity is through Glut4. Glut4 transports glucose into skeletal
muscle [14] and it has been shown that an over expression of Glut4
is associated with a fourfold increase in voluntary physical activity
[11].
Quantitative genetics rarely identify a mechanistic link relating
a potential candidate gene to the regulation of a phenotype. To
prove causal relationship, transgenic animals with targeted genes
knocked-out can be employed. However, a transgenic approach
can be confounded by the loss of regulatory regions in the genome
as well as developmental issues for the animal [15]. A tool that
could transiently silence a specific gene in vivo without confounding
effects would be ideal in identifying genes that regulate voluntary
physical activity and other phenotypes.
Morpholinos are anti-sense oligonucleotide analogs that bind to
complementary RNA sequences and inhibit processing of mRNA
by blocking translation or splicing of pre-mRNA [16]. While early
versions of morpholinos have been in use for over fifteen years
with in vitro applications, these early morpholino designs presented
several problems that prevented use in an in vivo model, including
rapid degradation by proteases/nucleases [17] and the inability of
the morpholino to cross membranes [18]. These problems were
solved when Marcos and colleagues [19] altered the delivery
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moiety of morpholinos by using eight guanidinium head groups of
arginine-rich peptides. The resulting oligonucleotide analog,
termed ‘‘Vivo-morpholinos,’’ are transported into the cell by
endocytosis and protected from proteases and nucleases [19].
Recently there has been evidence suggesting protein knockdown
can be achieved equally with intravenous (IV), intraperitoneal (IP),
or direct injection into targeted tissue [17,18,19,20].
To date there are only twenty-eight studies using Vivo-morpholinos
[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38-
,39,40,41,42,43,44] and all have reported at least 50% knockdown of
the target gene with no adverse side effects. Fourteen of these studies
used a mouse model [17,18,19,20,21,24,31,32,34,35,40,41,42,43]
with the remaining studies using rats [36,37], newts [29], chicken
embryos [27], fish [15,16,22,23,25,26] tadpoles [30,38], or frogs [28].
In the mouse models, it has been shown that Vivo-morpholinos were
equally efficacious with IV or IP, and recent studies have shown
success with direct injection in target tissue [36,37]. While these studies
have established the use of Vivo-morpholinos, they were limited in the
application parameters used. One of the major limitations of the initial
validation studies was the short-term nature of the studies (e.g. 24–
48 hours post treatment) even though it has been suggested [19] that
gene silencing with Vivo-morpholinos will theoretically last much
longer (e.g. 7 days). Further, the existing Vivo-morpholino studies
have only evaluated effects of a single Vivo-morpholino without
indication of whether multiple genes can be silenced simultaneously.
Additionally, there has been little success in applying Vivo-
morpholinos to the mouse brain [19].
Therefore, the purpose of this study was to validate the use of
Vivo-morpholinos in silencing targeted genes in a mouse model of
voluntary physical activity. This study included evaluation of the
Figure 1. Experiment 1, Vmat2 protein level in the nucleus
accumbens. Mean 6 standard deviation of western blot optical band
density and a representative western blot comparing Saline, Scramble
and Vivo-morpholino treated animals for Vmat2 protein expression in
the nucleus accumbens of the brain. There was no difference between
the treatment groups at four (p = 0.87, Panel A) or eleven (p = 0.14,
Panel B) days post treatment.
doi:10.1371/journal.pone.0061472.g001
Figure 2. Experiment 1, Vmat2 protein level in the soleus. Mean
6 standard deviation of western blot optical band density and a
representative western blot comparing Saline, Scramble and Vivo-
morpholino treated animals for Vmat2 protein expression in the soleus.
Panel A shows Vmat2 expression at four days post-last injection. There
was a significant decrease (p = 0.04) in Vivo-morpholino treated animals
compared to Saline and Scramble treated animals in Vmat2 expression
at four days post injection. Panel B shows Vmat2 expression at eleven
days post-last injection. There was a significant increase (p = 0.03) in
Vivo-morpholino treated animals compared to Saline and Scramble
treated animals in Vmat2 expression at eleven days post injection.
doi:10.1371/journal.pone.0061472.g002
Vivo-morpholinos and Voluntary Physical Activity
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appropriate control, the effectiveness of transporting a Vivo-
morpholino across the blood brain barrier (BBB) with a
pharmacological aid, the ability to combine multiple Vivo-
morpholinos in a ‘‘cocktail’’ to silence multiple genes simulta-
neously, and whether daily physical activity altered the washout
time course of an intravenous injected Vivo-morpholino.
Methods
Three separate experiments were used to fulfill the purposes of
this project. All experiments were approved by the Texas A&M
Institutional Animal Care and Use Committee (Animal use
protocols 2010-256, 2010-187, 2011-140, and 2011-147) and all
animals were housed in an AAALAC certified vivarium on a 12-
hour light/dark cycle with ad libitum access to standard chow and
water. Animals were monitored and efforts were taken to
ameliorate any animal suffering. All experiments used Vivo-
morpholinos ordered in the 400-nmole batches.
N Experiment 1: Evaluation of Vivo-morpholinos’ gene
silencing in mouse activity model
This experiment evaluated the effectiveness of silencing genes in
a physical activity model using Vivo-morpholinos, a method of
Vivo-morpholino delivery across the BBB, as well as the
appropriate control vehicle. Eighteen male C57Bl/6J mice
(Jackson Labs, Bar Harbor, ME) were randomly assigned to one
of three treatment groups:
Group 1) intravenously injected a translation-blocking Vivo-
morpholino (11 mg/kg) [19]; Gene Tools LLC, Philomath, OR)
targeting Vmat2 (Vmat2 group, n = 6);
Group 2) Intravenously injected a Vivo-morpholino scramble
control (11 mg/kg) which consisted of vehicle plus an oligonucle-
otide target (59-CCTCTTACCTCAGTTACAATTTATA-39)
that did not correspond to murine mRNA (Scramble group,
n = 6); and
Group 3) An intravenously injected control group that received
an equal volume (110 ul) of physiological saline (Saline group,
n = 6).
Preliminary experiments determined that systemically delivered
Vivo-morpholinos did not knockdown brain proteins [45]. Thus,
to facilitate Vivo-morpholino transport across the BBB, all
treatment groups received the bradykinin analog RMP-7
(6.5 mg/kg; Bachem, Prussia, PA) [46]. Pharmacological studies
have shown that using endogenous analogs of bradykinin [47]
increase permeability of the BBB while maintaining physiological
function of the animal [46]. Bradykinin activates b2 receptors on
endothelial cells of cerebral capillaries thereby disengaging tight
junctions and causing an increase in permeability of cerebral blood
vessels [46,47]. RMP-7 is a bradykinin analog that has several
benefits over bradykinin; specifically RMP-7 resists degradation,
has little to no toxicity to the brain, can be administered
intravenously, and is fast acting producing a result within
60 seconds of administration [47]. RMP-7 was initially developed
as a delivery method for chemotherapeutics in brain glioma
patients with studies showing a linear dose response between
RMP-7 and BBB permeability in conjunction with a variety of
chemotherapeutics [46].
At eight weeks of age mice were individually housed with
running wheels equipped with computers (Sigma Sport, St.
Charles, IL) to measure average daily distance run [48], and
beginning at nine weeks of age, completed a week of baseline
wheel running. At ten weeks of age, mice were randomly assigned
to one of the three treatment groups and received a tail vein
injection of the specific treatment for three consecutive days. At 11
weeks of age (4 days post the last injection) half the cohort was
sacrificed (n = 3 per treatment group). The activity of the
remaining mice was monitored for an additional week (recovery)
and the mice were then sacrificed.
At sacrifice, mice were anesthetized using vaporized isoflurane
followed by cervical dislocation. The soleus (peripheral slow twitch
muscle) and nucleus accumbens (reward center of the brain) were
removed and flash-frozen for later analysis. Gene silencing was
evaluated by determining protein knockdown using standard SDS-
Page and Western blotting techniques. Briefly, proteins were
extracted by placing the tissue in lysis buffer and homogenizing the
tissue with a motor and pestle. Protein concentration was
determined by Bradford assay to ensure equal amount of protein
loading per sample on the gel. The proteins were separated by
SDS-Page, and then transferred to a nitrocellulose membrane with
transfer confirmed by Ponceau S stain. Membranes were incubated
overnight in 1:1000 ratio of primary antibody recognizing Vmat2
(Cell Applications, San Diego, CA) and blocking buffer (5%
Nonfat Dried Milk, 0.5% Tween 20). Membranes were then
incubated in the secondary horseradish peroxidase antibody (Cell
Signaling Technology, Beverly, MA). Chemiluninescence was
imaged with a Flurochem analyzer (Derbyshire, UK) and the blot
was analyzed using the individual protein band’s optical density
that allowed for a semi-quantitative estimate of protein knock-
down.
The Western blot optical densities were analyzed using one-way
ANOVA to compare Vmat2 protein expression between the
treatments with an a priori alpha level of 0.05. Activity data was
analyzed using a 363 ANOVA with the main effects being
treatment group (i.e. Vmat2, Saline, or Scramble) and week of
treatment (i.e. baseline, injection, or recovery). If there was a
significant main-effect, a Tukey’s HSD post hoc (p,0.05) test was
employed. All statistical tests were carried out using GraphPad
Prism 5 (GraphPad Software Inc, La Jolla, CA).
N Experiment 2: Determination of Vivo-morpholino
Washout Period
To evaluate if physical activity altered the efficacy of the Vivo-
morpholino, 24 eight week old C57Bl/6J male mice (Jackson Labs,
Bar Harbor, ME) were individually housed and randomly assigned
Figure 3. Experiment 1, mouse wheel running. Average daily
distance ran for the baseline, injection, and recovery week for animals
treated with saline, Vivo-morpholino vehicle only (scramble) and the
Vivo-morpholino targeting Vmat2 (Vmat2). Vmat2 group significantly
(*p = 0.001) increased activity in the recovery week compared to the
baseline and injection week. There was no difference in physical activity
(p.0.05) in the scramble or saline treated animals for baseline,
injection, and recovery weeks.
doi:10.1371/journal.pone.0061472.g003
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to either a running wheel group (n = 12; unlocked wheels) or a
fixed wheel group (n = 12; locked wheels). The running wheel
group had free moving wheels attached to a computer as described
in Experiment 1. Each mouse in the fixed running wheel group
had a running wheel that was secured to prevent wheel movement.
Beginning at nine weeks of age, daily distance was measured in the
running wheel group using methods from Experiment 1. At ten
weeks of age one mouse from each group was sacrificed to
establish a baseline level of Vmat2 protein expression, while the
remaining mice received a concurrent tail vein injection of RMP-7
(6.5 ug/Kg) [46] and a Vivo-morpholino targeting Vmat2 (11 mg/
Kg) [19] for three consecutive days. Each day thereafter, one
mouse was sacrificed from each group to determine the washout of
the Vivo-morpholino and whether exposure to activity affected
protein knockdown.
On the day of sacrifice, mice were euthanized using vaporized
isoflurane and cervical dislocation, with subsequent harvesting of
the soleus and nucleus accumbens. Afterwards, proteins were
extracted from each sample and Vmat2 expression, as well as a-
synuclein (Cell Signaling, Danvers, MA), which has been shown to
be an indicator of Vmat2 transcription [49] were determined using
Western Blot techniques described in Experiment 1. The washout
data was then analyzed for linearity and if nonlinear, nonlinear
regression approaches were used to obtain R2 values for the
washout curves. The nonlinear data was then log transformed to
meet the parameters of a linear regression, which allowed the
comparison of the regression parameters between the locked and
unlocked running wheel groups. A p value of 0.05 was set a priori to
determine if the slopes and y intercepts were different from each
other. If there were no differences between the locked and
unlocked wheel groups, the data points were pooled. To facilitate
the comparison of baseline physical activity across the treatment
protocol, average daily distance measurements were pooled in
animals sacrificed in days 1–5 and days 6–10 of the protocol and
compared using a one-way ANOVA (a priori alpha value = 0.05).
Figure 4. Experiment 2, Evaluation of the washout time course of Vivo-morpholinos targeting Vmat2. Panels A, B, and C represent
soleus samples while panels D, E, and F represent nucleus accumbens samples. Panel A represents western blot data probing for Vmat2 in the soleus
for both unlocked wheel and locked wheel groups. Panel B is the optical density of the individual western blot bands from panel A. A nonlinear
regression was run on the data in panel B which generated an R2 = 0.65 for the animals on unlocked wheels and an R2 = 0.55 for animals on locked
wheels. Given there was no difference (p = 0.42) in the slope or y intercept of the unlocked wheel and locked wheel groups, the data were pooled at
each Day (Panel C). Panel C shows that there was a significant knockdown (+p= 0.001) in Vmat2 on days 2–6 and a significant (*p = 0.001) over
expression in Vmat2 on day 9 in the soleus. The same methodologies were applied to Panels D, E, and F for the nucleus accumbens. The nonlinear
regression resulted in R2 = 0.99 for the unlocked wheel group and R2 = 0.99 for the locked wheel group, and there was no difference (p = 0.66) in the
slope and y intercepts of the lines in panel E. Additionally Vmat2 was only significantly knocked down on Days 5 and 6 (+p= 0.001) with a significant
over expression (*p = 0.001) on Day 11. The mouse in the locked wheel group representing data for Day 11 was removed from analysis because it
developed malocclusion in the front incisors and became malnourished, thus altering physical activity level.
doi:10.1371/journal.pone.0061472.g004
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N Experiment 3: Utilization of a Vivo-morpholino Cocktail
Twelve, eight-week old male C57Bl/6J mice (Jackson Labs, Bar
Harbor, ME) were individually housed with running wheels as
described in Experiment 1 to measure average daily distance run.
At nine weeks of age mice completed a week of baseline wheel
running and then at ten weeks of age, randomly received a tail
vein injection of either the Vivo-morpholino cocktail (n = 6)
containing a Vivo-morpholino targeting Drd1 (11 mg/kg) [19] and
another Vivo-morpholino targeting Glut4 (11 mg/kg) [19] or
physiological saline (n = 6) for three consecutive days. Physiological
saline was used as a control since Experiment 1 showed no
difference in the activity response of physiological saline and Vivo-
morpholino scrambled control (see Results). At 11 weeks of age
(four days post-last injection), half the cohort was sacrificed to
evaluate the initial protein knockdown efficacy of the Vivo-
morpholino cocktail. The remaining mice ran for one week and
were then sacrificed. Upon sacrifice, the soleus was harvested and
protein expression of Drd1 (Cell Applications, San Diego, CA) and
Glut4 (Cell Applications, San Diego, CA) as well as the potential
compensatory proteins dopamine receptor 5 (Drd5, Proteintech
Group Inc, Chicago, IL) and glucose transporter 1 (Glut1, Cell
Applications, San Diego, CA) were determined using standard
Western blotting techniques, as described in Experiment 1. Similar
statistical analysis was used as in Experiment 1 with the exception
of a 263 ANOVA with the main effects being treatment (Saline or
Vivo-morpholino cocktail) and treatment week (Baseline, Injec-
tion, or Recovery).
Results
N Experiment 1: Evaluation of Vivo-morpholinos in activity
model
In the brain, treatment with a Vivo-morpholino targeting Vmat2
did not result in a significant knockdown of Vmat2 expression in
the nucleus accumbens of the brain four days after the last
morpholino injection as compared to saline or scramble treatment
(Figure 1, Panel A). However, there was a 79% knockdown
(p = 0.04) of Vmat2 in the soleus four days post-injection as
compared to both saline and scramble (Figure 2, Panel A).
Surprisingly, during the recovery week (11 days post treatment)
Vmat2 protein level had a significant 354% over expression in the
soleus of the Vmat2-Vivo-morpholino group compared to the
saline and scramble treatment (Figure 2, Panel B, p = 0.03). In the
nucleus accumbens (Figure 1) and the soleus (Figure 2) there was
no difference in Vmat2 expression between saline and scramble
treatments.
The initial reduction of Vmat2 in the soleus did not affect daily
physical activity (Figure 3). However, the Vmat2 group had a
significant 139% increase in activity during the recovery week as
compared to the baseline and injection week (Figure 3, p = 0.001),
which corresponded to the Vmat2 over-expression observed in the
soleus eleven days post-injection (Figure 2, Panel B).
N Experiment 2: Determination of Vivo-morpholino
Washout Period
The evaluation of the washout time course of Vivo-morpholinos
targeting Vmat2 showed there was a significant (p = 0.001) 55%
knockdown of Vmat2 in the soleus on Days 2–6 (Figure 4 Panels A
and C) with a significant 129% over expression observed on Day 9
(p = 0.001). There was no difference (p = 0.74) between the
washout curves for the animals who had access to a running
wheel (R2 = 0.65) compared to those that had a locked running
wheel (R2 = 0.55) (Figure 4 Panel B).
In the nucleus accumbens, there were similar observations as in
the soleus. There was a significant 74% knockdown in Vmat2
(Figure 4 Panels D and F) on Days 5–6 (p = 0.001) with a 988%
over expression on Day 11 (p = 0.001). Additionally there was no
difference in the washout curves (p = 0.66) for animals on wheels
(R2 = 0.99) or locked wheels (R2 = 0.99) (Figure 4 Panel E).
To confirm the over expression of Vmat2, western blot analysis
was performed probing for a-synuclein, which is an indicator of
Vmat2 transcription [49]. The results showed that in the brain on
Days 2 and 7 there was a 275% increase a-synuclein protein level
(Figure 5).
There was no difference (p.0.05) in physical activity level of the
running wheel group between the baseline week and days 1–5
post-injection (Figure 6). During days 6–10 of the washout
protocol there was a significant 164% increase in physical activity
(p = 0.0016) versus baseline and days 1–5, corresponding to the
increase in Vmat2 expression during the same time period
(Figure 4).
Figure 5. Experiment 2, a-synuclein protein level in nucleus
accumbens. Western blot analysis probing for a-synuclein to confirm
the signal for the over expression of Vmat2 protein seen in the nucleus
accumbens. There was an increase in a-synuclein at days 2 and 7–10. a-
synuclein is an indicator of Vmat2 transcription thus when Vmat2 was
knocked down by the Vivo-morpholino there was an increased stimulus
placed on the cell to transcribe more Vmat2.
doi:10.1371/journal.pone.0061472.g005
Figure 6. Experiment 2, mouse wheel running. Average daily
distance ran for animals treated with Vivo-morpholino targeting Vmat2
for the baseline week, injection week (Days 1–5), and recovery week
(Days 6–10) of washout protocol. Physical activity was significantly
(*p = 0.0016) increased in Days 6–10.
doi:10.1371/journal.pone.0061472.g006
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N Experiment 3: Utilization of a Vivo-morpholino Cocktail
Western blot analysis showed that there was significant
knockdown in Drd1 (97%) protein (Figure 7, Panel A, p = 0.01)
and Glut4 (60%) protein (Figure 7, Panel A, p = 0.042) in the
soleus four days after the last injection. Expression of both Drd1
and Glut4 returned to control levels during the recovery week (11
days post injection, Figure 7, Panel B). With the Vivo-morpholino
cocktail treatment (Drd1 and Glut4) there was no change in
physical activity at any time period (Figure 8, p = 0.15).
To evaluate potential compensation for the decreases in Drd1
and Glut4, Drd5 and Glut1 were probed by western blotting
(Figure 9). There was no difference in Drd5 protein levels between
control and treatment at four days post treatment (p = 0.22) or
eleven days post treatment (p = 0.93). There was also no difference
in Glut1 protein levels between control and treatment at four days
post treatment (p = 0.56) or eleven days post treatment (p = 0.36).
Discussion
A molecular biology tool that can transiently silence genes in a
whole-animal model will significantly advance the capability to
determine cause-effect relationships between specific genes and
targeted phenotypes. We have found that the use of Vivo-
morpholinos targeting Vmat2, Drd1, and Glut4 resulted in transient
protein knock-down in the skeletal muscle up to four days after the
last application. While the use of a pharmacological agent to
facilitate Vivo-morpholino delivery across the blood brain barrier
seemed promising, our results indicate marginal knockdown in the
brain as compared to the soleus when using RMP-7. Further, we
observed that concurrent physical activity did not influence the
action of Vivo-morpholinos on Vmat2 protein expression. Maybe
most importantly, we also observed that the use of multiple Vivo-
morpholinos in a cocktail would knock down more than one
protein at a time in skeletal muscle. Interestingly, while initial
knockdown of these proteins did not affect physical activity, we
observed an increased physical activity coincident with post-
washout over-expression of Vmat2.
The search for an in vivo technique to transiently silence genes
has been pursued for several decades with numerous promising
tools identified including antisense oligonucleotides, small inter-
fering RNA (siRNA), and phosphorodiamidate morpholino
oligomers (PMO). Antisense oligonucleotides are effective at gene
silencing yet are highly unstable in body fluids and are rapidly
degraded [17]. Initially, siRNA promised to transiently silence
genes but presented difficulty with in vivo applications [44], which
Figure 7. Experiment 3, Drd1 and Glut4 protein level. Western
blot and mean6 standard deviation of optical densities of soleus tissue
that underwent the Vivo-morpholino cocktail treatment. Panel A
represents four days post treatment of Drd1 and Glut4 expression
comparing controls to Vivo-morpholino cocktail treated animals. There
was a significant knockdown for both Drd1 (p = 0.01) and Glut4
(p = 0.04). Panel B represents eleven days post treatment of Vivo-
morpholino cocktail. There was no difference between control and Drd1
(p = 0.79) and Glut4 (p = 0.58) expression.
doi:10.1371/journal.pone.0061472.g007
Figure 8. Experiment 3, mouse wheel running. Average daily
distance ran for baseline, injection, and recovery week for animals
treated saline (control) and the morpholino cocktail targeting Drd1 and
Glut4 (Vivo-morpholino). There was no difference (p = 0.15) between
the activity of the control group and the morpholino group.
doi:10.1371/journal.pone.0061472.g008
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has limited siRNA’s usefulness in integrative physiology. PMOs
resist degradation in vivo yet have been associated with increased
toxicity [17]. Morpholinos, which are a form of antisense
oligonucleotides, have had several modifications to their structure
to limit toxicity and improve gene silencing which led to the
development of the more stable Vivo-morpholino [19]. Addition-
ally, the fact that we observed no change in daily physical activity
with the vivo-morpholino delivery vehicle (scramble) makes the
Vivo-morpholino ideal for the investigation of candidate genes
associated with physical activity.
Our results showed that Drd1-, Glut4-, and Vmat2-targeted Vivo-
morpholinos significantly knocked down Drd1, Glut4, and Vmat2
protein expression in skeletal muscle by an average 97%, 60%,
and 79%, respectively. Furthermore, the use of the Vivo-
morpholino cocktail showed that simultaneous protein knockdown
was possible. Previous studies have shown that treatment with
Vivo-morpholinos at a similar dosage as used in this study (i.e.
11 mg/kg) resulted in 50–70% knockdown [16,26], similar to the
knockdown amounts we observed. Recent literature [43] suggests
that to obtain 100% protein knockdown, the Vivo-morpholino
dosage must be 160% greater than the amount prescribed by the
manufacturer (i.e. 17.6 mg/kg) or the Vivo-morpholino injections
must be given regularly over the course of the study [17,20]. The
fact that there were differences in the magnitude of Drd1 and
Glut4 knockdown suggests that the nature of the target gene also
may play a role in the magnitude of gene silencing. Genes coding
for proteins that exhibit faster turnover rates in skeletal muscle
may require the higher Vivo-morpholino dose. Therefore, protein
turnover characteristics should be considered as a design
parameter in Vivo-morpholino protocols.
Our initial results with Vivo-morpholinos in brain tissue were
not promising due to a potential lack of BBB penetration [45].
Vivo-morpholinos are ,10,000 Daltons in size and the BBB
prevents substances greater than 400 Daltons from reaching the
brain [46], thus we utilized RMP-7 as means to facilitate Vivo-
morpholino delivery across the BBB. Unfortunately, in spite of the
potential benefits of using RMP-7, Experiment 1 did not show
significant knockdown in the nucleus accumbens of Vmat2 protein
when using RMP-7 on day four after the injection. Interestingly,
we did observe Vmat2 knockdown in the nucleus accumbens in
Experiment 2 on Days 5 and 6 after the last injection, which was
outside of our measurement range in Experiment 1. We suspect
that due to the high activity of the dopamine system in the brain
[50,51,52], there may be a decreased protein turnover rate of
Vmat2 in the brain as compared to skeletal muscle [50,53,54,55]
resulting in a slower protein turnover rate leading to a slower
knockdown time course of Vmat2 in the brain. Thus, while the use
of RMP-7 appears to have facilitated some knockdown of Vmat2
in the brain, knockdown of brain genes using vivo-morpholinos
needs to be carefully designed to optimize both knock-down
magnitude and time-course.
Surprisingly, in both Experiments 1 and 2, we observed a
rebound over expression of Vmat2 protein compared to baseline
during the recovery week in both skeletal muscle and nucleus
accumbens. To our knowledge, this rebound phenomena has not
been reported in the Vivo-morpholino literature. We would
suggest that this rebound over-expression was actually the result of
the feedback loop that controls Vmat2 [55]. Speculatively, with
the blocking of Vmat2 mRNA and a reduction of Vmat2 protein
concentration, the cell would have been stimulated to transcribe
more Vmat2. With subsequent Vmat2 production being blocked by
the Vivo-morpholino, the stimulus to produce more Vmat2 mRNA
would become further elevated compared to the initial days of
treatment. Once the Vivo-morpholino was degraded and
Figure 9. Experiment 3, Drd5 and Glut1 protein level. Western
blot and mean6 standard deviation of optical densities of soleus tissue
that underwent the Vivo-morpholino cocktail treatment. Panel A
represents four days post treatment of Drd5 and Glut1 protein
expression comparing controls to Vivo-morpholino cocktail treated
animals. There was not a significant knockdown for either Drd5
(p = 0.22) or Glut1 (p = 0.56). Panel B represents eleven days post
treatment of Vivo-morpholino cocktail. There was no difference
between control and Drd5 (p = 0.93) and Glut1 (p = 0.36) expression.
doi:10.1371/journal.pone.0061472.g009
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removed, the elevated signal to produce Vmat2 would result in an
increased translation of Vmat2 mRNA [55] and over-expression of
Vmat2 protein. This hypothesis is supported by our observation of
a significant increase in a-synuclein in the nucleus accumbens on
Day 2, with a continued increased signaling from Day 7 and
peaking on Day 10 (Figure 5). Whereas a-synuclein has been
observed to be an indicator of the cell’s stimulus to transcribe
Vmat2 [49], it appears that once Vmat2 was knocked down there
was an increase in the stimulus to transcribe Vmat2 which resulted
in the over expression of Vmat2 in the recovery week. While we
did not observe a rebound over expression with either of the other
genes we investigated (Drd1 and Glut4), the possibility of such a
rebound effect occurring with other genes is potentially an
intriguing way to use Vivo-morpholinos to explore consequences
of both gene under expression and over expression in the same
model.
It has been previously suggested that Drd1, Glut4, and Vmat2 are
potential candidate genes for the regulation of physical activity
[1,6,7,8,10,13] with Glut4 in particular, showing a direct effect on
activity when over expressed [11]. Thus, we were somewhat
surprised that knockdown of both Drd1 and Glut4 simultaneously
in soleus (Experiment 3) did not affect activity levels. However, our
observed lack of effect of Glut4 and Drd1 knockdown on physical
activity in spite of an observed 60% and 97% protein reduction,
respectively, could have reflected a general redundancy in these
physiological systems. For example, it has been shown that with a
50% reduction in Glut4 there is no apparent change in muscle
physiology because of a compensatory Glut1 over-expression for
the loss of Glut4 [56,57]. Therefore, we evaluated possible
compensation in these two systems by analyzing Drd5 and Glut1
protein levels. We observed no differences in Drd5 or Glut1 levels
between control and treatment groups suggesting that compensa-
tion for the knock down of Glut4 or Drd1 did not occur and
therefore, neither Glut4 nor Drd1 are primary peripheral
regulating genes in voluntary activity. However, in spite of these
results, it is clear that future studies can take advantage of the use
of vivo-morpholino cocktails to silence multiple genes at once to
consider their phenotypic effects.
Vmat2 was an attractive knockdown target for the regulation of
physical activity given its proven role in the development of
Parkinson disease [10]. However, we observed no change in
activity with a decrease in peripheral Vmat2 in Experiments 1 and
2. However, the rebound of Vmat2 observed in the soleus
(Experiment 1 and 2) and nucleus accumbens (Experiment 2)
along with the associated increase in physical activity could
provide a potential explanation for the regulation of voluntary
physical activity. It has been shown that the dopamine system in
skeletal muscle affects muscle force production [8] and in the brain
affects reward driven behavior [6]. When mice are given, artificial
dopamine there is an associated hyperactivity response
[50,51,54,58]. We would suggest that as the effects of the Vivo-
morpholinos wore off and Vmat2 expression returned and
surpassed baseline, there was an increase in extracellular
dopamine that elicited the hyperactive effects similar to artificially
administering dopamine. Further, this extracellular dopamine
would have increased skeletal muscle tone and force production
[8,59] as well as reward driven behavior [6], which would have
further increased physical activity.
The purpose of these experiments was to evaluate the efficacy of
a potential transient gene-silencing tool, the Vivo-morpholino,
when used in a physical activity model for an extended period of
time. We observed that Vivo-morpholinos that targeted Vmat2,
Drd1 or Glut4 significantly reduced associated protein expression in
skeletal muscle up to four days after treatment with a subsequent
recovery to baseline levels in Drd1 and Glut4 and with an over
expression in Vmat2. Physical activity during the treatment did
not affect the time course of protein knockdown. The delivery
vehicle used (scramble Vivo-morpholino) did not affect protein
knockdown or physical activity. Further, we found that multiple
Vivo-morpholinos given in a cocktail knocked down multiple
proteins simultaneously. While knocking-down any of the targeted
genes did not result in hypothesized reductions in physical activity,
a rebound of Vmat2 protein was associated with an increase in
physical activity during the same time as the rebound. We
conclude that the use of Vivo-morpholinos can be a powerful tool
to transiently silence specific genes and determine whether those
genes are causally related to a phenotype of interest, especially
when the targeted gene’s protein characteristics, such as turnover
rate and location, are used to strengthen the research design.
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